INVITATION
Bristol Myers Squibb - The future is now: Transforming management of GI cancer with immuno-oncology
INVITATION
MSD - Translating immuno-oncology biomarkers into clinical practice
INVITATION
Daiichi Sankyo - Antibody Drug Conjugates (ADCs): Advancements in the treatment of solid tumours
INVITATION
Bristol Myers Squibb - Exploring the current and evolving landscape in thoracic cancers
INVITATION
Sanofi Genzyme - Immune checkpoint blockade in non-melanoma skin cancer
INVITATION
GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
INVITATION
Kite, a Gilead Company - Optimising the patients’ CAR T-cell journey
INVITATION
MSD - Multiple immunotherapeutic options: Clinical decision making in advanced renal cell carcinoma and urothelial carcinoma
INVITATION
F. Hoffmann-La Roche Ltd. - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
INVITATION
TouchIME - PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities